Clinical and Commercial Manufacturing of mRNA Therapeutics: Opportunities and Challenges

The emergence of COVID-19 led to the rapid progression and commercial validation of mRNA vaccines and the lipid nanoparticle (LNP) technology underpinning this new drug modality. However, the industry still faces significant challenges navigating the evolving manufacturing and regulatory landscape. This interactive panel discussion will address:
- Manufacturing strategies to expand LNP delivery to new applications such as cancer vaccines and personalized medicine
- How decreasing scale will impact the processes and workflows of biopharma manufacturers
- Regulatory considerations for each development phase to improve efficiency and safety